Your browser doesn't support javascript.
loading
Predictive capacity for local disease control of neogenin-1 (NEO1) transcriptional expression in patients with head and neck squamous cell carcinoma.
León, Xavier; Valero, Cristina; Fuster, Gemma; Bragado, Paloma; Camacho, Mercedes; Avilés-Jurado, Francesc-Xavier.
Affiliation
  • León X; Otorhinolaryngology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, C/Mas Casanovas, 90, 08041, Barcelona, Spain.
  • Valero C; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.
  • Fuster G; Facultad de Medicina, UVIC, Universitat Central de Catalunya, Vic, Spain.
  • Bragado P; Otorhinolaryngology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, C/Mas Casanovas, 90, 08041, Barcelona, Spain. cvalero@santpau.cat.
  • Camacho M; Department of Biomedicine and Department of Biochemistry and Molecular Biomedicine, University of Barcelona (UB) and Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain.
  • Avilés-Jurado FX; Biosciences Department, Sciences Technology and Engineering Faculty, Tissue Repair and Regeneration Group, UVIC, Vic, Spain.
Clin Transl Oncol ; 2024 Jun 19.
Article de En | MEDLINE | ID: mdl-38898351
ABSTRACT

PURPOSE:

To analyze the predictive capacity for local disease control of the transcriptional expression of neogenin-1 (NEO1) gene in patients with head and neck squamous cell carcinoma (HNSCC). METHODS/PATIENTS A retrospective study was performed on tumor biopsies from 107 patients with HNSCC treated surgically. The transcriptional expression of NEO1 was determined by RT-PCR. NEO1 transcriptional expression value was categorized according to local disease control by recursive partitioning analysis.

RESULTS:

Lower NEO1 transcriptional expression was associated with worse local control after surgical treatment. Patients with lower NEO1 expression (n = 25, 23.4%) had a 5-year local recurrence-free survival of 61.8% (95% CI 42.1-81.5%), while patients with higher NEO1 expression (n = 82, 76.6%) had a 5-year local recurrence-free survival of 85.6% (95% CI 77.6-93.6%), (P = 0.003). According to the result of multivariable analysis, patients with lower NEO1 expression had a 2.7-fold increased risk of local tumor recurrence (95% CI 1.0-7.0, P = 0.043) compared to patients with higher NEO1 expression.

CONCLUSIONS:

HNSCC patients with a lower transcriptional expression of NEO1 have a significantly higher risk of local recurrence after surgical treatment.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Clin Transl Oncol Année: 2024 Type de document: Article Pays d'affiliation: Espagne

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Clin Transl Oncol Année: 2024 Type de document: Article Pays d'affiliation: Espagne